Bortezomib is a drug owned by Maia Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2042. Details of Bortezomib's patents and their expiration are given in the table below.
Patent strength
6
/ 10
Filter patents by
Country
: United States (US)
Argentina (AR)
Australia (AU)
Brazil (BR)
Canada (CA)
Chile (CL)
China (CN)
India (IN)
Japan (JP)
Mexico (MX)
Paraguay (PY)
Philippines (PH)
Russia (RU)
Singapore (SG)
South Africa (ZA)
Thailand (TH)
United States (US)
Uruguay (UY)
Eurasian Patent Organization (EA)
World Intellectual Property Organization (WO)
Taiwan (TW)
European Patent Office (EP)
Patent Category
: All
All
Combination
Compound
Device
Dosage Regimen
Formulation
Other Forms
Polymorph
Process
Use Method
Dosage Form Category
: Others
Implantable
Inhalation
Injectable
OPHTHALMIC
Oral Liquid
Oral Solid
Rectal/Vaginal
Topical
Transdermal
Others
NEW
Get the complete list right in your inbox!
Contact Us
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration
(oral, tablet,
capsules, liquids etc).
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list of recent legal activities going on the following
patents of Bortezomib.
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but
Bortezomib is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Bortezomib's family patents as well as insights into
ongoing legal events
on those patents.
Bortezomib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Bortezomib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Bortezomib's
generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 23, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bortezomib Generic
API
suppliers:
Bortezomib is the generic name
for
the brand Bortezomib.
22 different companies have already filed for the generic of Bortezomib, with Gland having the maximum number of approved applications.
Check out the entire list of companies
who have already received approval for Bortezomib's
generic
Alternative Brands for
Bortezomib
Bortezomib
which is used for treating adult patients with multiple myeloma., has several other brand drugs using the same active ingredient (Bortezomib).
Given below is the list of those companies and their brand drugs, to help you identify new
opportunities, assess
competitors, and plan your market strategies more effectively.
Bortezomib is a drug owned by Maia Pharmaceuticals Inc. It is used for treating adult patients with multiple myeloma. Bortezomib uses Bortezomib as an active ingredient. Bortezomib was launched by Maia in 2022.
Approval Date:
Bortezomib was approved by
FDA for market
use on 27 July, 2022.
Bortezomib
is used for treating adult patients with multiple myeloma.
Dosage:
Bortezomib
is available in solution form for intravenous use. Given below is detailed information on Dosage -
Strength
Dosage Form
Availability
Application Pathway
3.5MG/3.5ML (1MG/ML)
SOLUTION
Discontinued
INTRAVENOUS
3.5MG/1.4ML (2.5MG/ML)
SOLUTION
Discontinued
INTRAVENOUS
Bortezomib Patent Expiration
Bortezomib is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 03, 2032. Details of Bortezomib's patents and their expiration are given in the table below.
Patent strength
6
/ 10
Filter patents by
Country
: United States (US)
Argentina (AR)
Australia (AU)
Brazil (BR)
Canada (CA)
Chile (CL)
China (CN)
India (IN)
Japan (JP)
Mexico (MX)
Paraguay (PY)
Philippines (PH)
Russia (RU)
Singapore (SG)
South Africa (ZA)
Thailand (TH)
United States (US)
Uruguay (UY)
Eurasian Patent Organization (EA)
World Intellectual Property Organization (WO)
Taiwan (TW)
European Patent Office (EP)
Patent Category
: All
All
Combination
Compound
Device
Dosage Regimen
Formulation
Other Forms
Polymorph
Process
Use Method
Dosage Form Category
: Others
Implantable
Inhalation
Injectable
OPHTHALMIC
Oral Liquid
Oral Solid
Rectal/Vaginal
Topical
Transdermal
Others
NEW
Get the complete list right in your inbox!
Contact Us
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration
(oral, tablet,
capsules, liquids etc).
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Bortezomib's patents.
Latest Legal Activities on Bortezomib's Patents
Given below is the list of recent legal activities going on the following
patents of Bortezomib.
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but
Bortezomib is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Bortezomib's family patents as well as insights into
ongoing legal events
on those patents.
Bortezomib's Family Patents
Bortezomib has
patent protection in a total of 4 countries. It's US patent count contributes only to 50.0% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Bortezomib.
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Bortezomib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Bortezomib's
generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 03, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Bortezomib Generic
API
suppliers:
Bortezomib is the generic name
for
the brand Bortezomib.
22 different companies have already filed for the generic of Bortezomib, with Gland having the maximum number of approved applications.
Check out the entire list of companies
who have already received approval for Bortezomib's
generic
Alternative Brands for
Bortezomib
Bortezomib
which is used for treating adult patients with multiple myeloma., has several other brand drugs using the same active ingredient (Bortezomib).
Given below is the list of those companies and their brand drugs, to help you identify new
opportunities, assess
competitors, and plan your market strategies more effectively.
Bortezomib is a drug owned by Fresenius Kabi Usa Llc. It is used for treating adult patients with multiple myeloma. Bortezomib uses Bortezomib as an active ingredient. Bortezomib was launched by Fresenius Kabi in 2017.
Approval Date:
Bortezomib was approved by
FDA for market
use on 06 November, 2017.
